Background Amivantamab has been approved for the treatment of patients with advanced
non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 …

Epidermal growth factor receptor (EGFR) actively involves in modulation of various cancer
progression related mechanisms including angiogenesis, differentiation and migration …

Epidermal growth factor receptor (EGFR) is essential for normal cellular functions. Mutations
of EGFR's kinase domain can cause dysregulation leading to non-small cell lung cancer …

Introduction EGFR exon 20 insertion (ex20ins) mutations represent 5% to 10% of EGFR
mutations in NSCLC. Identifying patients with EGFR ex20ins is challenging owing to the …

The development of targeted therapy in epidermal growth factor receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …

Introduction Patients with advanced, epidermal growth factor receptor (EGFR)-mutated, non-
small cell lung cancer (NSCLC) with Exon 20 insertion mutations (Exon20ins) have poor …

Introduction The ideal management of patients with unresectable non-small-cell lung cancer
(NSCLC) is still developing. Unresectable NSCLC has a high mortality rate and poor …

Background: Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions
(EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs) …

Insertions in the epidermal growth factor receptor (EGFR) exon 20 (Ex20Ins) are the third
most incident mutations in non-small cell lung cancer (NSCLC). The hypervariable nature of …

Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades,
the management of non-small cell lung cancer (NSCLC) has undergone a significant …